Search

everythinglearnresearchcommunity

for

Search:↓

A parasite-derived molecule speeds up skin healing and affects immune cell behavior without increasing scarring.

CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.

Most patients improved in both atopic dermatitis and alopecia areata with certain treatments, but some had worsened symptoms, suggesting personalized care is needed.

The patient's symptoms improved with treatment but recurred when the steroid dose was reduced, requiring ongoing therapy.

JAK inhibitors show promise in treating difficult skin diseases.

Elagolix did not effectively treat polycystic ovary syndrome.

Upadacitinib effectively treats skin conditions like eczema and psoriasis and is becoming more widely used and affordable.

Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.

Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.

Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.

Tofacitinib taken by mouth helps treat hair loss in children.

Topical clobetasol is recommended over mycophenolate mofetil for treating Lichen Planopilaris due to better safety and patient satisfaction.

Anti-DFS70 antibodies can help identify nonsystemic autoimmune conditions in SLE patients.

JAK inhibitors can help treat alopecia areata but have risks and high costs.

Tocilizumab might be an effective treatment for COVID-19.

Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.

Rheumatology clinics should always provide preconception counseling for women on DMARDs.

Collaborative care between physicians and pharmacists improved medication management for rheumatoid arthritis without raising costs.

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.

High-dose UVA-1 therapy improves symptoms and skin condition in sclerosing skin disease.

Lanadelumab greatly reduces hospital visits and angioedema episodes, improving life quality for hereditary angioedema patients.

Baricitinib is an effective treatment for severe alopecia areata.

Omalizumab may cause temporary hair loss, especially in women aged 18-60.

High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.

Secukinumab effectively treated a difficult case of folliculitis decalvans.

Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.